Literature DB >> 27913996

Altered Gut Microbiota Composition and Immune Response in Experimental Steatohepatitis Mouse Models.

Mitsuaki Ishioka1, Kouichi Miura2, Shinichiro Minami1, Yoichiro Shimura3, Hirohide Ohnishi1.   

Abstract

BACKGROUND: Although several types of diet have been used in experimental steatohepatitis models, comparison of gut microbiota and immunological alterations in the gut among diets has not yet been performed. AIM: We attempted to clarify the difference in the gut environment between mice administrated several experimental diets.
METHODS: Male wild-type mice were fed a high-fat (HF) diet, a choline-deficient amino acid-defined (CDAA) diet, and a methionine-choline-deficient (MCD) diet for 8 weeks. We compared the severity of steatohepatitis, the composition of gut microbiota, and the intestinal expression of interleukin (IL)-17, an immune modulator.
RESULTS: Steatohepatitis was most severe in the mice fed the CDAA diet, followed by the MCD diet, and the HF diet. Analysis of gut microbiota showed that the composition of the Firmicutes phylum differed markedly at order level between the mice fed the CDAA and HF diet. The CDAA diet increased the abundance of Clostridiales, while the HF diet increased that of lactate-producing bacteria. In addition, the CDAA diet decreased the abundance of lactate-producing bacteria and antiinflammatory bacterium Parabacteroides goldsteinii in the phylum Bacteroidetes. In CDAA-fed mice, IL-17 levels were increased in ileum as well as portal vein. In addition, the CDAA diet also elevated hepatic expression of chemokines, downstream targets of IL-17.
CONCLUSIONS: The composition of gut microbiota and IL-17 expression varied considerably between mice administrated different experimental diets to induce steatohepatitis.

Entities:  

Keywords:  Gut microbiota; Gut–liver axis; IL-17; Nonalcoholic fatty liver disease; Nonalcoholic steatohepatitis

Mesh:

Substances:

Year:  2016        PMID: 27913996     DOI: 10.1007/s10620-016-4393-x

Source DB:  PubMed          Journal:  Dig Dis Sci        ISSN: 0163-2116            Impact factor:   3.199


  51 in total

Review 1.  Association between Helicobacter spp. infections and hepatobiliary malignancies: a review.

Authors:  Fany Karina Segura-López; Alfredo Güitrón-Cantú; Javier Torres
Journal:  World J Gastroenterol       Date:  2015-02-07       Impact factor: 5.742

2.  Beneficial effect of oral administration of Lactobacillus casei strain Shirota on insulin resistance in diet-induced obesity mice.

Authors:  E Naito; Y Yoshida; K Makino; Y Kounoshi; S Kunihiro; R Takahashi; T Matsuzaki; K Miyazaki; F Ishikawa
Journal:  J Appl Microbiol       Date:  2011-02-01       Impact factor: 3.772

3.  Characterization of fecal microbial communities in patients with liver cirrhosis.

Authors:  Yanfei Chen; Fengling Yang; Haifeng Lu; Baohong Wang; Yunbo Chen; Dajiang Lei; Yuezhu Wang; Baoli Zhu; Lanjuan Li
Journal:  Hepatology       Date:  2011-06-26       Impact factor: 17.425

4.  Oral administration of Parabacteroides distasonis antigens attenuates experimental murine colitis through modulation of immunity and microbiota composition.

Authors:  M Kverka; Z Zakostelska; K Klimesova; D Sokol; T Hudcovic; T Hrncir; P Rossmann; J Mrazek; J Kopecny; E F Verdu; H Tlaskalova-Hogenova
Journal:  Clin Exp Immunol       Date:  2010-11-19       Impact factor: 4.330

5.  The interleukin-17 pathway is involved in human alcoholic liver disease.

Authors:  Arnaud Lemmers; Christophe Moreno; Thierry Gustot; Raphaël Maréchal; Delphine Degré; Pieter Demetter; Patricia de Nadai; Albert Geerts; Eric Quertinmont; Vincent Vercruysse; Olivier Le Moine; Jacques Devière
Journal:  Hepatology       Date:  2009-02       Impact factor: 17.425

6.  Inhibiting triglyceride synthesis improves hepatic steatosis but exacerbates liver damage and fibrosis in obese mice with nonalcoholic steatohepatitis.

Authors:  Kanji Yamaguchi; Liu Yang; Shannon McCall; Jiawen Huang; Xing Xian Yu; Sanjay K Pandey; Sanjay Bhanot; Brett P Monia; Yin-Xiong Li; Anna Mae Diehl
Journal:  Hepatology       Date:  2007-06       Impact factor: 17.425

7.  Specific microbiota-induced intestinal Th17 differentiation requires MHC class II but not GALT and mesenteric lymph nodes.

Authors:  Duke Geem; Oscar Medina-Contreras; Michelle McBride; Rodney D Newberry; Pandelakis A Koni; Timothy L Denning
Journal:  J Immunol       Date:  2014-06-04       Impact factor: 5.422

8.  The phylogeny of the genus Clostridium: proposal of five new genera and eleven new species combinations.

Authors:  M D Collins; P A Lawson; A Willems; J J Cordoba; J Fernandez-Garayzabal; P Garcia; J Cai; H Hippe; J A Farrow
Journal:  Int J Syst Bacteriol       Date:  1994-10

Review 9.  Desulfovibrio desulfuricans bacteremia and review of human Desulfovibrio infections.

Authors:  Ellie J C Goldstein; Diane M Citron; Victoria A Peraino; Sally A Cross
Journal:  J Clin Microbiol       Date:  2003-06       Impact factor: 5.948

Review 10.  The role of intestinal bacteria overgrowth in obesity-related nonalcoholic fatty liver disease.

Authors:  Silvia M Ferolla; Geyza N A Armiliato; Cláudia A Couto; Teresa C A Ferrari
Journal:  Nutrients       Date:  2014-12-03       Impact factor: 5.717

View more
  20 in total

1.  The day will come to treat HCC in a drugstore?

Authors:  Kouichi Miura
Journal:  Hepatobiliary Surg Nutr       Date:  2017-12       Impact factor: 7.293

2.  Publisher Correction: The gut-liver axis and the intersection with the microbiome.

Authors:  Anupriya Tripathi; Justine Debelius; David A Brenner; Michael Karin; Rohit Loomba; Bernd Schnabl; Rob Knight
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2018-12       Impact factor: 46.802

3.  Differential Activation of Hepatic Invariant NKT Cell Subsets Plays a Key Role in Progression of Nonalcoholic Steatohepatitis.

Authors:  Igor Maricic; Idania Marrero; Akiko Eguchi; Ryota Nakamura; Casey D Johnson; Suryasarathi Dasgupta; Carolyn D Hernandez; Phirum Sam Nguyen; Austin D Swafford; Rob Knight; Ariel E Feldstein; Rohit Loomba; Vipin Kumar
Journal:  J Immunol       Date:  2018-10-15       Impact factor: 5.422

Review 4.  Characterization of diet based nonalcoholic fatty liver disease/nonalcoholic steatohepatitis in rodent models: Histological and biochemical outcomes.

Authors:  Ghaidafeh Akbari; Seyyed Ali Mard; Feryal Savari; Barat Barati; Maryam J Sameri
Journal:  Histol Histopathol       Date:  2022-04-27       Impact factor: 2.130

Review 5.  Animal Models of Fibrosis in Nonalcoholic Steatohepatitis: Do They Reflect Human Disease?

Authors:  David H Ipsen; Jens Lykkesfeldt; Pernille Tveden-Nyborg
Journal:  Adv Nutr       Date:  2020-11-16       Impact factor: 8.701

Review 6.  The gut-liver axis and the intersection with the microbiome.

Authors:  Anupriya Tripathi; Justine Debelius; David A Brenner; Michael Karin; Rohit Loomba; Bernd Schnabl; Rob Knight
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2018-07       Impact factor: 46.802

Review 7.  Animal Models of Nonalcoholic Fatty Liver Disease-A Starter's Guide.

Authors:  Mikhaïl A Van Herck; Luisa Vonghia; Sven M Francque
Journal:  Nutrients       Date:  2017-09-27       Impact factor: 5.717

8.  Effect of atorvastatin on the gut microbiota of high fat diet-induced hypercholesterolemic rats.

Authors:  Tariq Jamal Khan; Youssri M Ahmed; Mazin A Zamzami; Saleh A Mohamed; Imran Khan; Othman A S Baothman; Mohamed G Mehanna; Muhammad Yasir
Journal:  Sci Rep       Date:  2018-01-12       Impact factor: 4.379

9.  16S rRNA gene-based association study identified microbial taxa associated with pork intramuscular fat content in feces and cecum lumen.

Authors:  Shaoming Fang; Xingwei Xiong; Ying Su; Lusheng Huang; Congying Chen
Journal:  BMC Microbiol       Date:  2017-07-19       Impact factor: 3.605

10.  Tumor necrosis factor-α-mediated hepatocyte apoptosis stimulates fibrosis in the steatotic liver in mice.

Authors:  Yosuke Osawa; Ekumi Kojika; Yukiko Hayashi; Masamichi Kimura; Koji Nishikawa; Sachiyo Yoshio; Hiroyoshi Doi; Tatsuya Kanto; Kiminori Kimura
Journal:  Hepatol Commun       Date:  2018-02-13
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.